41 results on '"van Gelder, Michel"'
Search Results
2. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
3. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
4. First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
5. The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine
6. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
7. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
8. Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
9. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
10. Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
11. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation
12. Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
13. Time-Restricted Versus Standard Duration Immunosuppression after Allogeneic Hematopoietic Stem Cell Transplantation: Results from the Prospective Randomized Phase III HOVON-96 Trial
14. Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors
15. Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant
16. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
17. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
18. Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT
19. Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
20. Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
21. Salvage Use of Ibrutinib after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for B Cell Malignancies: A Study of the French Cooperative Group for CLL, the French Soceity for Blood and Marrow Transplantation (SFGM-TC), and the European Society for Blood and Marrow Transplantation (EBMT) Chronic Malignancy and Lymphoma Working Parties
22. Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT)
23. Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT)
24. Allogeneic Hematopoietic Transplantation in Patients with CLL: Results of a Large Disease-Specific Risk Factor Analysis
25. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
26. Long-Term Follow-up Data Support the Curative Potential of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis from the Chronic Malignancies Working Party of the EBMT
27. Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric
28. Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: A Phase II Randomized Study from the Belgian Hematological Society
29. R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation
30. First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
31. R-DHAP Immuno-Chemotherapy Is An Effective Remission-Induction Treatment for Fludarabine Refractory CLL Patients and Allows the Majority to Proceed to Allogeneic Stem Cell Transplantation. Results of the Planned Interim Analysis of the Dutch-Belgian Prospective Multicenter HOVON88 Trial,
32. First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,
33. Sufficient and Timely Autologous Stem Cell Harvest After Chemoimmunotherapy with Alemtuzumab In Combination with Bi-Weekly CHOP as First Line Treatment In Systemic Peripheral T-Cell Lymphomas (PTCL): a Feasibility Analysis From the First Randomized Trial In Systemic PTCL (ACT trial)
34. Effective Alloreactive NK Cell Therapy for Breast Cancer In Mice Requires Conditioning with Cyclophosphamide and Total Body Irradiation but Not Bone Marrow Engraftment
35. Complex Karyotype Predicts Outcome Better Than Monosomal Karyotype In Patients with MDS/Secondary Acute Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): a Retrospective Survey on Behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
36. T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis.
37. R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.
38. Alloreactive NK-Cells Cure Tumor Stem Cell Containing Breast Cancer.
39. Monosomal Karyotype Predicts Poor Outcome for MDS/sAML Patients with Chromosome 7 Abnormalities After Allogeneic Stem Cell Transplantation for MDS/sAML. A Study of the MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
40. Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study.
41. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.